See All Slides - tctmd.com

Slides

Presentation Controversies and Advances 2023

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Presenter: Michael J. Bloch

November 30, 2023

Presentation Controversies and Advances 2023

Anti-inflammatory Drugs to Inhibit Atherosclerosis: Old and New

Presenter: Christie M. Ballantyne

November 30, 2023

Presentation Controversies and Advances 2023

Decline in STEMI and Rising Prevalence of Non-obstructive CAD; What are the Contributing Risk Factors and Plaque Change?

Presenter: C. Noel Bairey Merz

November 30, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

Presentation AHA 2023

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Presenter: Dike Ojji

November 17, 2023

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

Presentation AHA 2023

Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients

Presenter: William T. Abraham

November 15, 2023

Presentation AHA 2023

AZALEA-TIMI 71

Presenter: Christian T. Ruff

November 15, 2023

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

Advertisement

Slides

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Anti-inflammatory Drugs to Inhibit Atherosclerosis: Old and New

Decline in STEMI and Rising Prevalence of Non-obstructive CAD; What are the Contributing Risk Factors and Plaque Change?

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients

AZALEA-TIMI 71

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content